Section 32 has led a $46.7m series B round that will support further development of the MIT spinout's biosensor-based diagnostics device.
Glympse Bio, a US-based disease management technology spinout of Massachusetts Institute of Technology (MIT) completed a $46.7m series B round on Wednesday that was led by venture capital firm Section 32.
Biopharmaceutical company Gilead Sciences, Temasek, DNS Capital, New Leaf Venture Partners, Waterman Ventures, Catalio Capital Management, Arch Venture Partners, CRV, GreatPoint Ventures and Polaris Partners’ LS Polaris Innovation Fund filled out the round.
Glympse will use the capital to further development of its biosensor system, which is…
